CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT-A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL

被引：0
|
作者：
Tuttle, Katherine [1 ]
Bain, Stephen C. [2 ]
Cherney, David [3 ]
Lawson, Jack [4 ]
Rasmussen, Soren [4 ]
Vrhnjak, Blaz [4 ]
Khunti, Kamlesh [5 ]
机构：
[1] Univ WA Providence Hlth, Spokane, WA 99258 USA
[2] Swansea Univ, Med Sch, Swansea, W Glam, Wales
[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Leicester, Leics, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO462
引用
收藏
页码：I331 / I331
页数：1
相关论文
共 50 条
  • [1] Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial
    Tuttle, Katherine R.
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Khunti, Kamlesh
    Rasmussen, Soren
    Sokareva, Ekaterina
    Cherney, David Z.
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (07): : 2006 - 2015
  • [2] KIDNEY DISEASE OUTCOMESWITH SEMAGLUTIDE VERSUS PLACEBO ACROSS BASELINE KDIGO RISK CATEGORIES: A POST HOC ANALYSIS OF SUSTAIN 6
    Tuttle, Katherine
    Bain, Stephen C.
    Bosch-Traberg, Heidrun
    Cherney, David
    Rasmussen, Soren
    Sokareva, Ekaterina
    Khunti, Kamlesh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I145 - I146
  • [3] EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
    Tuttle, Katherine
    Cherney, David
    Hadjadj, Samy
    Idorn, Thomas
    Mosenzon, Ofri
    Perkovic, Vlado
    Rasmussen, Soren
    Wolthers, Benjamin
    Bain, Stephen C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 152 - 152
  • [4] Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
    Wang, Jingyu
    Yang, Juhong
    Jiang, Wenhui
    Liu, Wenyan
    Shen, Zewei
    Gao, Zhongai
    Chang, Baocheng
    DIABETES OBESITY & METABOLISM, 2024,
  • [5] Semaglutide treatment and renal function in the SUSTAIN 6 trial
    Silver, R.
    Gumprecht, J.
    Vilsboll, T.
    Hansen, T.
    Pettersson, J.
    Vrazic, H.
    Wilding, J.
    DIABETOLOGIA, 2018, 61 : S40 - S41
  • [6] Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Petrie, Mark
    Bain, Stephen
    Hoff, Soren Tetens
    Johansen, Nicklas
    Rasmussen, Soren
    Vilsboell, Tina
    Husain, Mansoor
    CIRCULATION, 2021, 144
  • [7] Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Rossing, P.
    Bain, S.
    Bosch-Traberg, H.
    Frenkel, O.
    Heerspink, H. L.
    Rasmussen, S.
    Mellbin, L.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S24 - S25
  • [8] Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6
    Stephen C. Bain
    Nicolas Belmar
    Søren T. Hoff
    Mansoor Husain
    Søren Rasmussen
    Tina Vilsbøll
    Mark C. Petrie
    Diabetes Therapy, 2025, 16 (1) : 15 - 28
  • [9] Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
    Husain, Mansoor
    Consoli, Agostino
    De Remigis, Alessandra
    Meyer, Anna Sina Pettersson
    Rasmussen, Soren
    Bain, Stephen
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [10] Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
    Strain, W. David
    Frenkel, Ofir
    James, Martin A.
    Leiter, Lawrence A.
    Rasmussen, Soren
    Rothwell, Peter M.
    Ripa, Maria Sejersten
    Truelsen, Thomas C.
    Husain, Mansoor
    STROKE, 2022, 53 (09) : 2749 - 2757
12345